Tokyo, Oct. 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063326) titled 'A study to evaluate the effectiveness and safety of tirzepatide injection in patients with type 2 diabetes' on Oct. 20.
Study Type:
Observational
Primary Sponsor:
Institute - Meitetsu hospital
Condition:
Condition - Type 2 diabetes
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The aim of this study is to evaluate the effectiveness and safety of subcutaneous tirzepatide in patients with type 2 diabetes mellitus in clinical practice.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with type 2 diabetes mellitus treated at our institution
Patients who received subcutaneous tirzepatide
Patients with available clinical data before and after treatment initiation
Patients with at least 12 months of follow-up
Key exclusion criteria - Patients referred to other institutions and lost to follow-up
Patients who discontinued tirzepatide on their own
Patients who discontinued tirzepatide treatment
Patients with less than 12 months of follow-up
Target Size - 100
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2023 Year 06 Month 01 Day
Date of IRB - 2024 Year 07 Month 17 Day
Anticipated trial start date - 2023 Year 07 Month 01 Day
Last follow-up date - 2024 Year 07 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070148
Disclaimer: Curated by HT Syndication.
